These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

607 related items for PubMed ID: 10630830

  • 1. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA, McVoy HJ, Kaul AF.
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [Abstract] [Full Text] [Related]

  • 2. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S, Stirling AL.
    Am J Health Syst Pharm; 2000 Apr 15; 57(8):739-46. PubMed ID: 10786259
    [Abstract] [Full Text] [Related]

  • 3. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep 15; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 4. Candesartan cilexetil: an update of its use in essential hypertension.
    Easthope SE, Jarvis B.
    Drugs; 2002 Sep 15; 62(8):1253-87. PubMed ID: 12010090
    [Abstract] [Full Text] [Related]

  • 5. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S.
    Am J Hypertens; 2000 Jan 15; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [Abstract] [Full Text] [Related]

  • 6. Candesartan cilexetil. A review of its use in essential hypertension.
    McClellan KJ, Goa KL.
    Drugs; 1998 Nov 15; 56(5):847-69. PubMed ID: 9829158
    [Abstract] [Full Text] [Related]

  • 7. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
    Melian EB, Jarvis B.
    Drugs; 2002 Nov 15; 62(5):787-816. PubMed ID: 11929332
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R, Högemann AM, Sunzel M, Riddell JG.
    J Hum Hypertens; 1997 Sep 15; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M, Chatellier G, Guyene TT, Ménard J.
    J Hypertens; 1999 Apr 15; 17(4):561-8. PubMed ID: 10404959
    [Abstract] [Full Text] [Related]

  • 10. Candesartan cilexetil: a review of its preclinical pharmacology.
    Nishikawa K, Naka T, Chatani F, Yoshimura Y.
    J Hum Hypertens; 1997 Sep 15; 11 Suppl 2():S9-17. PubMed ID: 9330999
    [Abstract] [Full Text] [Related]

  • 11. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH.
    J Hum Hypertens; 2000 Apr 15; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [Abstract] [Full Text] [Related]

  • 12. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
    Inada Y, Ojima M, Kanagawa R, Misumi Y, Nishikawa K, Naka T.
    J Hum Hypertens; 1999 Jan 15; 13 Suppl 1():S75-80. PubMed ID: 10076925
    [Abstract] [Full Text] [Related]

  • 13. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS.
    J Hypertens Suppl; 1997 Dec 15; 15(6):S9-12. PubMed ID: 9493121
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K, Kahan T, Dahl M.
    Am J Hypertens; 2000 May 15; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [Abstract] [Full Text] [Related]

  • 15. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.
    Eur J Clin Pharmacol; 1998 Sep 15; 54(7):497-501. PubMed ID: 9832289
    [Abstract] [Full Text] [Related]

  • 16. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G, Fuchs W.
    Curr Med Res Opin; 2005 Jun 15; 21(6):935-40. PubMed ID: 15969893
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P.
    Blood Press Suppl; 2000 Jun 15; 1():27-30. PubMed ID: 11059633
    [Abstract] [Full Text] [Related]

  • 18. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS.
    Blood Press Suppl; 2000 Jun 15; 1():19-22. PubMed ID: 11059631
    [Abstract] [Full Text] [Related]

  • 19. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM, Keating GM.
    Am J Cardiovasc Drugs; 2010 Jun 15; 10(5):335-42. PubMed ID: 20860416
    [Abstract] [Full Text] [Related]

  • 20. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
    Lacourcière Y, Asmar R.
    Am J Hypertens; 1999 Dec 15; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.